Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Time to Sell?

Key Points

• Shares plunged 12.8% to $261.27 from a $299.45 close on Wednesday, with just 105 shares traded—about 67% below average—indicating a sharp, low‑volume selloff.
• The stock is trading below both its 50‑day ($276.49) and 200‑day ($295.24) moving averages
• Bio‑Rad reported $1.89 EPS for the quarter with a net margin of 6.52% and ROE of 3.56%, and shows strong liquidity (current ratio 3.21) and low leverage (debt/equity 0.12) while operating in Life Science and Clinical Diagnostics.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report)'s stock price traded down 12.8% on Wednesday . The stock traded as low as $261.27 and last traded at $261.27. 105 shares traded hands during trading, a decline of 67% from the average session volume of 317 shares. The stock had previously closed at $299.45.

Bio-Rad Laboratories Trading Up 1.1%

The stock's 50 day moving average is $276.49 and its 200-day moving average is $295.24. The company has a market cap of $7.05 billion, a P/E ratio of 43.04 and a beta of 0.96. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $1.89 earnings per share for the quarter. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad's product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.